louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01291849: The Effect-site Concentration of Remifentanil for Preventing Cough During Emergence From Balanced Anesthesia for Nasal Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cough
Keywords: nasal surgery
endoscopic sinus surgery
septoplasty
Cough
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2011-02-09
Enrollment: 24
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: After nasal surgery, emergence cough or straining will produce venous engorgement and increase bleeding from the surgical site, so the necessity for smooth extubation without severe cough during emergence provides a challenge for the anesthetists. Recently, remifentanil is commonly used short-acting opioid, and several studies have demonstrated the antitussive effect of remifentanil via effect-site target-controlled infusion during emergence. However, there may be gender difference in response to opioid, and the previous studies about antitussive effect of remifentanil are targeted at female patients and there is no investigation of effect site concentration of remifentanil for male patients undergoing nasal surgery. The purpose of this study is to evaluate the effect-site concentration of remifentanil via target-controlled infusion for preventing cough in man after sevofluorane balanced anesthesia.


Eligibility criteria: Inclusion Criteria:

* all male aged 18-60 years
* ASA(American Society of Anesthesiologists)physical status I or II
* who underwent ESS(endoscopic sinus surgery)or septoplasty under sevoflurane-remifentanil balanced anesthesia

Exclusion Criteria:

* predicted difficult airway,
* BMI(Body Mass Index) of more than 30 kg/m2,
* chronic respiratory disease,
* recent respiratory track infection,
* chronic coughing,
* significant cardiovascular,
* hepatic or renal disease,
* current smokers
* medical history of medication of opioid or ACEI(angiotensin covering enzyme inhibitor)

Primary outcomes:
measure: cough incidence
timeFrame: from sevoflurane discontinuation (at the end of anesthesia) to 5 min after extubation
measure: cough grade
timeFrame: from sevoflurane discontinuation (at the end of anesthesia) to 5 min after extubation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
citation: Lee B, Lee JR, Na S. Targeting smooth emergence: the effect site concentration of remifentanil for preventing cough during emergence during propofol-remifentanil anaesthesia for thyroid surgery. Br J Anaesth. 2009 Jun;102(6):775-8. doi: 10.1093/bja/aep090. Epub 2009 May 2.
Clinical trial NCT05822349: Effect of Using Pictograms on Improving Depression and Anxiety Among Type 2 Diabetic Patients.
Official title: Impact of Using Pictograms as an Educational Strategy on Improving Patient Depression and Anxiety Among Low Health Literate Patients With Type 2 Diabetes at Northern Badya Hospital, Jordan.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type 2 Diabetes
Lead sponsor: University of Jordan
Sponsor class: OTHER
First posted: 2023-04-20
Enrollment: 204
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: we will study the impact of using pictograms on improving depression and anxiety among type 2 diabetic patients, we suppose that patients who received pictograms-enriched labels will have lower levels of depression and anxiety in comparison with those who will not receive after three month follow-up evaluation.


Eligibility criteria: Inclusion Criteria:

* Participants are eligible if they are Jordanian adults, aged 18 or older, who have been clinically diagnosed with T2DM for at least 6 months, having low health literacy (Individuals who obtained 66 or lower scores in the full TOFHLA instrument are considered as individuals with "low literacy" in the study) \[24\], come personally for the refill.

Exclusion Criteria:

* Patients who are unable to communicate verbally (aphasic or with hearing impairment), those with any visual, learning disabilities, and psychological or hepatorenal disease (according to the clinical diagnosis by a physician), and those deemed too ill or frail to attend the clinic, and who have participated in other diabetes education research projects will be excluded.

Primary outcomes:
measure: change in depression level
timeFrame: 12 weeks following ends of intervention
measure: change in anxiety level
timeFrame: 12 weeks following ends of intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Mafraq
country: Jordan
facility: Northern Badya Hospital
Study officials:
affiliation: University of Jordan
name: AL-Motassem F Yousef
role: STUDY_DIRECTOR
References:
Clinical trial NCT05213949: An Observational Study of Risk Factors and Long-term Prognosis of Patients With Liver Abscess in the "Real-world"
Official title: An Observational Study of Risk Factors and Long-term Prognosis of Patients With Pyogenic Liver Abscess in the "Real-world"
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver Abscess, Pyogenic
Liver Abscess
Abscess
Infections
Keywords: Pyogenic Liver abscess
Liver histological change
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2022-01-28
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients older than 18 years of age admitted for pyogenic liver abscesses

Brief summary: Pyogenic liver abscess is one of the most common visceral abscesses, its incidence is increasing worldwide. According to the previous literature, the mortality rate of pyogenic liver abscess is as high as 31% and become a serious social health problem. However, the data of prospective observational real-world studies are scarce and no relevant research of the liver histological change has been reported, so the long-term prognosis and the risk factors for pyogenic liver abscess are still unknown. Patients will be followed up prospectively for a period of 2 years and observed clinical prognosis (all-cause mortality, the recurrence rate, and the rehospitalization rate). The investigators will investigate the predictive value of clinical risk factors for clinical prognosis and establish clinical prediction models to predict the long-term prognosis of pyogenic liver abscesses.


Eligibility criteria: Inclusion Criteria:

* Patients older than 18 years of age;
* Irrespective of gender;
* Symptomatic patients of liver abscess confirmed with radiology imaging, either by ultrasonography or computed tomography scan.

Exclusion Criteria:

* Patients \<18 years old;
* Pregnancy at presentation.

Primary outcomes:
measure: Proportion and causes of deaths within 2 years of discharge from hospital
timeFrame: 2 years
measure: Proportion and causes of re-hospitalization within 2 years of discharge from hospital
timeFrame: 2 years
Secondary outcomes:
measure: The recurrence rate of pyogenic liver abscess
timeFrame: 2 years
measure: The number of participants with Histological Change in the Liver
timeFrame: 2 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: NanFang Hospital of Southern Medical University
state: Guangdong
Study officials:
References:
Clinical trial NCT04829149: Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea
Official title: A Cohort Study for Comparison of Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration and Statin Prescription Patterns in Patients With Dyslipidemia in Korea.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dyslipidemias
Keywords: Statin
Rosuvastatin
New onset DM
LDL-C
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2021-04-02
Enrollment: 5717
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A Korean dyslipidemia patient who is taking or is scheduled to take statins therapy or Rosuzet tablets

Brief summary: A Cohort Study for Comparison of Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration and Statin Prescription Patterns in Patients With Dyslipidemia in Korea.

Detailed description: The main objective of this study is to evaluate the effect of reducing LDL-C levels after 12 months of administration of Statin Monotherapy or Rosuzet Tab.(Rosuvastatin/Ezetimibe) in patients with dyslipidemia in Korea

Eligibility criteria: Inclusion Criteria:

1. Age≥19
2. Subject who is taking or is scheduled to take Statins therapy or Rosuzet Tab.
3. Not diagnosed with diabetes
4. Subject who can written informed consent voluntarily
5. Subject can continue to participate for 12 months on Study

Exclusion Criteria:

1. Patients for whom use of Rosuzet Tab. and Statin therapy is prohibited (e.g. patient who are hypersensitive to the main or compositional component of this drug, patient with active liver disease, patient with severe renal failure, patient using combinations with cyclosporin)
2. A pregnant or nursing woman

Primary outcomes:
measure: Lipid profiles
timeFrame: 12 months
Secondary outcomes:
measure: Lipid profiles
timeFrame: 6 months
measure: Lipid profiles
timeFrame: 6, 12 months
measure: Occurrence and aspect of new onset diabetes and adverse events
timeFrame: 12 months
measure: Prescription rate
timeFrame: 12 months
measure: Reason for medication change
timeFrame: 12 months
measure: Medication compliance
timeFrame: 12 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hanmi Pharmaceutical Company Limited
Study officials:
affiliation: Hanmi Pharmaceutical Company Limited
name: Mi-Jeung KIM
role: STUDY_DIRECTOR
References:
Clinical trial NCT04995549: SKin Uncertainties Modeling
Official title: Construction of a Mechanical Data Base for Mathematically Modeling Uncertainties in Human Skin Tissues
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Unrecognized Condition
Keywords: skin, non lesional, arm
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2021-08-09
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The study is based on measurement device and will provide a database of viscoelastic properties of the forearm skin among healthy volunteers.

These data will be used to develop a mathematical model representative of the mechanical behavior of the skin.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers aged 18 to 50 years old
* non-opposition to participating in SKUM study
* Affiliation to french social security

Exclusion Criteria:

* Refusal to participate
* Volunteer with any skin disease likely to interfere with the primary outcome
* Legal incapacity or limited legal capacity
* Subject unlikely to cooperate with the study and / or weak cooperation
* Subject without health insurance
* Pregnant woman
* Subject being in the period of exclusion from another study

Primary outcomes:
measure: Height of displacement (mm) of a skin disc.
timeFrame: Month 1
Secondary outcomes:
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de besançon
Study officials:
affiliation: CHU DE BESANCON
name: Brice CHATELAIN, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02894749: Evaluation of 3D Rotational Angiography After EVAR
Official title: Evaluation of 3D Rotational Angiography After EVAR
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Radiation Burn
Aortic Aneurysm, Abdominal
Keywords: hybrid rooms
cone-beam computed tomography
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
Collaborators: name: GE Healthcare
First posted: 2016-09-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This is a randomized prospective monocentric study to evaluate the benefits of a 3D rotational acquisition (3DRA) to assess technical success after treatment of infra-renal aneurysm with bifurcated endograft. Patients will be randomized between the standard strategy (2D angiography at the end of the procedure and angioCT-scan before discharge) and the new strategy (3DRA at the end of the procedure). Expected findings are a reduction of radiation exposure and contrast medium used during the hospital stay, with a similar resolution between angioCT-scan and 3DRA to depict the main complications after EVAR (occlusion, kinking, endoleak). Furthermore, any complication depicted after 3DRA group could benefit from an additional procedure during the same operating time, and therefore avoid a second intervention for the patient.


Eligibility criteria: Inclusion Criteria:

* Patients treated with EVAR for infra-renal aortic aneurysm
* In a hybrid room
* With a signed consent

Exclusion Criteria:

* Pregnant women
* Patients unable to understand the study protocol or to give their consents
* Renal insufficiency (eGFR\<60mL/min)
* Ruptured aneurysms and other emergency settings

Primary outcomes:
measure: Effective Dose
timeFrame: Single 1 day - At patient discharge
Secondary outcomes:
measure: Contrast Medium
timeFrame: Single 1 day - At patient discharge
measure: Reintervention rate
timeFrame: During the first 30 days
measure: Additional procedure
timeFrame: During surgery
Other outcomes:
Locations:
city: Lille
country: France
facility: Hôpital Cardiologique, CHRU
Study officials:
affiliation: University Hospital, Lille
name: Stephan Haulon, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04336449: Eptinezumab in Healthy Japanese Subjects
Official title: Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Eptinezumab in Healthy Japanese Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: H. Lundbeck A/S
Sponsor class: INDUSTRY
First posted: 2020-04-07
Enrollment: 18
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate how eptinezumab enters, moves through and exits the body. Safety and tolerability will also be investigated.

Detailed description: The study will consist of 18 healthy Japanese subjects, divided into two single dose cohorts with 9 subjects in each cohort.

Eligibility criteria: Inclusion Criteria:

* Healthy Japanese subjects with a BMI of ≥ 18.5 and ≤ 25 kg/m2

Other in- and exclusion criteria may apply

Primary outcomes:
measure: Cmax eptinezumab
timeFrame: From dosing to week 12
measure: AUC(0-t) eptinezumab
timeFrame: From dosing to week 12
measure: AUC(0-inf) eptinezumab
timeFrame: From dosing to week 12
measure: Systemic Clearance of eptinezumab
timeFrame: From dosing to week 12
Secondary outcomes:
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: P-One Clinic
Study officials:
affiliation: LundbeckClinicalTrials@Lundbeck.com
name: Email contact via H. Lundbeck A/S
role: STUDY_DIRECTOR
References:
Clinical trial NCT02044549: Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section
Official title: Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postpartum Hemorrhage
Blood Loss
Keywords: Carbetocin
syntometrine
postpartum hemorrhage
cesarean section
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2014-01-24
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of Postpartum hemorrhage after cesarean section

Detailed description: A double blind randomized study conducted on 450 pregnant subjected randomly either to single 100 μg IV dose of carbetocin (150 women) or combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.

Prevention of postpartum haemorrhage (PPH) after cesarean section (CS) had been evaluated by measurement of drop of Hemoglobin and hematocrit, incidence of PPH and number of subjects needed additional oxytocic

Eligibility criteria: Inclusion Criteria:

* All participants are at 37 - 40 weeks of gestational age
* Noncomplicated pregnancy.

Exclusion Criteria:

* Participants with placenta previa
* Patients with coagulopathy
* preeclamptic women
* known sensitivity to oxytocin or methergine were excluded

Primary outcomes:
measure: prevention of post partum hemorrhage after CS
timeFrame: 24 hours
Secondary outcomes:
measure: side effects of drugs used
timeFrame: 24 hours
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ahmed Maged
Study officials:
affiliation: Ass prof kasr aini medical school
name: Ahmed Maged, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05847049: Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy
Official title: Influence of Combined Eplerenone , Intravitreal Aflibercept and Topical Nepafenac Therapy on Serous Foveal Detachment in Central Serous Chorioretinopathy (CSCR)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Central Serous Chorioretinopathy
Lead sponsor: Dar El Oyoun Hospital
Sponsor class: OTHER
First posted: 2023-05-06
Enrollment: 16
Sex: ALL
Minimum age (years): 16
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021

Brief summary: describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR

Detailed description: Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021

After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac.

Investigators collected and recorded the following data:

* Age
* Gender
* Systemic hypertension (present or not)
* Smoking (Yes / No)
* Best corrected visual acuity (BCVA) (baseline, final)
* Central macular thickness (CMT) (baseline, final)
* Serous detachment Height (SDH) (baseline, final)
* Duration of Follow-up ( in months)

Eligibility criteria: Inclusion Criteria:

* CSCR eyes treated by combination of Eplerenone, Aflibercept and Nepafenac.

Exclusion Criteria:

* • CSCR treated by other modalities

  * CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac

Primary outcomes:
measure: Change in central macular thickness (CMT ) in microns
timeFrame: (baseline, 6 months)
measure: Change in serous detachment height (SDH) in microns
timeFrame: (baseline, 6 months)
Secondary outcomes:
measure: Change in BCVA
timeFrame: (baseline, 6 months)
measure: Duration of Follow-up ( in months)
timeFrame: (baseline, 6 months)
measure: Complications (Eplerenone, Aflibercept, and nepafenac)
timeFrame: (baseline, 6 months)
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr alainy faculty of medicine
Study officials:
References:
Clinical trial NCT05431049: Anesthesia Type on Percutaneous Nephrolithotomy in Aging Male
Official title: The Effect of Anesthesia Type on the Outcomes of Percutaneous Nephrolithotomy in Aging Male
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Stone
Anesthesia
Lead sponsor: Bursa City Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Bursa City Hospital
First posted: 2022-06-24
Enrollment: 184
Sex: MALE
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Above 65 years of age, male sex and having kidney stone

Brief summary: The aim of this study is to compare the anesthesia methods in percutaneous nephrolithotomy in terms of safety and effectiveness in elderly men.

Detailed description: Data recorded since 2003 will be analyzed retrospectively. Elderly men with PNL will be divided into two groups according to the type of anesthesia. The results determined in both arms will be compared with appropriate statistical methods.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Renal Stone Disease
* Above 65 years of age
* Male sex

Exclusion Criteria:

* Having low hemoglobin level before surgery
* Presence of hematology disease causing bleeding diathesis
* Presence of stones in an ectopic or transplanted kidney

Primary outcomes:
measure: Stone free rates
timeFrame: Post-surgery day 1
measure: Complication rates
timeFrame: During surgery to 24 hours after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Bursa
country: Turkey
facility: Bursa City Hospital
Study officials:
References:
Clinical trial NCT01649349: The Feasibility Study of Dual-Section Nasogastric Tube
Official title: The Feasibility Study of Dual-Section Nasogastric Tube in Dysphagia Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Stroke
Mouth Neoplasms
Lead sponsor: Changhua Christian Hospital
Sponsor class: OTHER
First posted: 2012-07-25
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this studyis to assess the feasibility and safety of novel designed two-piece nasogastric tube.


Eligibility criteria: Inclusion Criteria:

* dysphagia
* mouth neoplasms
* stroke
* already use conventional nasogastric tube for at least 2 weeks

Exclusion Criteria:

* unconsciousness patient
* unstable medical condition with needs of closely medical care
* unable to fill in inform consent
* the fixed length was less than 50 or more than 60 centimeter when using conventional nasogastric tube

Primary outcomes:
measure: Number of Participants with Adverse Events
timeFrame: participants will be followed for the duration of hospital stay, an expected average of 1 weeks
Secondary outcomes:
measure: satisfaction of Dual-Section Nasogastric Tube
timeFrame: participants will be followed for the duration of hospital stay, an expected average of 1 weeks
Other outcomes:
Locations:
Study officials:
References: